The trial’s findings showed that the ribociclib+ alpelisib+ letrozole combination caused a more consistent reduction of Ki-67, suggesting that targeting both CDK4/6 and PI3K may lead to better health outcomes for BC patients [97]. This evidence concerns the gene CDK4 and breast cancer.